-
1.发明公开NUCLEIC ACID CONSTRUCT INCLUDING NUCLEIC ACID DERIVED FROM GENOTYPE 3a HCV GENOME 审中-公开NUKLEINSÄUREKONSTRUKTMIT EINER AUS EINEM GENOM DES GENOTYPS 3A-HCV GEWONNENENNUKLEINSÄURE
公开(公告)号：EP2752485A1
公开(公告)日：2014-07-09
申请号：EP12827627.6
申请日：2012-08-31
申请人： JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES , INSERM - Institut National de la Santé et de la Recherche Médicale , Toray Industries, Inc.
CPC分类号： C07K14/005 , C07K16/109 , C12N7/00 , C12N2770/24221 , C12N2770/24222 , C12N2770/24234 , C12Q1/18 , G01N33/5008 , G01N33/5767 , G01N2333/186
摘要： This invention provides a nucleic acid comprising, in the following order, a 5' untranslated region comprising a particular nucleotide sequence of the genome of hepatitis C virus genotype 3a; a nucleotide sequence encoding a particular amino acid sequence of an NS3 protein, a nucleotide sequence encoding a particular amino acid sequence of an NS4A protein, a nucleotide sequence encoding a particular amino acid sequence of an NS4B protein, a nucleotide sequence encoding a particular amino acid sequence of an NS5A protein, a nucleotide sequence encoding a particular amino acid sequence of an NS5B protein of the hepatitis C virus genotype 3a; and a 3' untranslated region comprising a particular nucleotide sequence of a genome of hepatitis C virus genotype 3a.
摘要翻译： 本发明提供一种包含以下顺序的包含丙型肝炎病毒基因型3a基因组特定核苷酸序列的5'非翻译区的核酸; 编码NS3蛋白的特定氨基酸序列的核苷酸序列，编码NS4A蛋白的特定氨基酸序列的核苷酸序列，编码NS4B蛋白的特定氨基酸序列的核苷酸序列，编码特定氨基酸的核苷酸序列 NS5A蛋白的序列，编码丙型肝炎病毒基因型3a的NS5B蛋白的特定氨基酸序列的核苷酸序列; 和包含丙型肝炎病毒基因型3a的基因组的特定核苷酸序列的3'非翻译区。
-
公开(公告)号：EP4349976A1
公开(公告)日：2024-04-10
申请号：EP22811031.8
申请日：2022-03-31
申请人： Mican Technologies Inc. , Japan as Represented by The Director-General of National Institute of Infectious Diseases , OSAKA UNIVERSITY
发明人： SUZUKI, Ryosuke , MATSUDA, Mami , MURAMATSU, Masamichi , SAITO, Kyoko , FUKASAWA, Masayoshi , HANADA, Kentaro , YAMANAKA, Atsushi , MIYAZAKI, Kazuo , YAMADA, Misuzu , SHIMIZU, Jun
摘要： The present invention aims to provide a method for testing the function of antibodies that uses safe antigens and gives results more quickly. The present invention relates to a method for determining antibody-dependent enhancement ability of antibodies, including contacting, in the presence of a test antibody, Fcγ receptor-expressing cell with single round infectious virus particles containing a gene with a region encoding a labeled protein and a region encoding non-structural (NS) proteins 1 to 5 of the yellow fever virus genome, a capsid protein of a virus, and an outer shell protein (Envelope) of a virus, wherein when the measured label is greater than that of a negative control cell, the test antibody is determined to have an antibody-dependent enhancement ability, and the like.
-
公开(公告)号：EP3530674A1
公开(公告)日：2019-08-28
申请号：EP17861867.4
申请日：2017-10-19
申请人： Denka Company Limited , Tokyo Institute of Technology , The Kitasato Institute , JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
发明人： UENO Takafumi , YOSHIKAWA Kengo , MANO Megumi , KATAYAMA, Kazuhiko , MIKI, Motohiro , TODAKA, Reiko , TAKAHASHI, Yoshimasa , ONODERA, Taishi
IPC分类号： C07K19/00 , A61K39/125 , A61P31/12 , C07K7/08 , C07K14/00 , C07K14/005 , C07K14/08 , C12N15/09 , C12P21/02
摘要： The present invention addresses the issue of providing: a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration, that is capable of easily immunizing target cells; a molecular needle aggregate being an effective component thereof; and a production method therefor. A norovirus component vaccine is provided that has as an effective component thereof an aggregate including a hexamer having two molecules of a trimer of a molecular needle indicated by formula (1) bound thereto. W-L 1 -X n -Y (1) [In the formula, W indicates a P domain amino acid sequence in a norovirus capsid protein that is the immunogen, L 1 indicates a first linker sequence having 0-100 amino acids, X indicates an amino acid sequence of SEQ ID No. 1, Y indicates an amino acid sequence in a cell introduction area, and n indicates an integer of 1-3.]
-
公开(公告)号：EP2615104B1
公开(公告)日：2017-03-22
申请号：EP11823616.5
申请日：2011-09-07
申请人： Saitama Medical University , JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES , NOF CORPORATION
IPC分类号： C07K7/06 , A61K9/127 , A61K39/29 , A61K39/39 , A61P31/14 , C12N5/0783 , C12N15/117
CPC分类号： A61K47/6911 , A61K31/7088 , A61K39/12 , A61K39/29 , A61K47/544 , A61K2039/55555 , A61K2039/572 , A61K2039/6018 , C12N7/00 , C12N15/117 , C12N2310/17 , C12N2710/24143 , C12N2770/24234
摘要： The present invention provides a peptide-bound liposome wherein the peptide contains a partial amino acid sequence having a length of not less than 9 amino acids in the amino acid sequence of hepatitis C virus NS3 protein, has a length of 9 to 11 amino acids, and is capable of inducing cytotoxic T lymphocytes, the liposome contains a phospholipid containing an acyl group having 14 to 24 carbon atoms and one unsaturated bond or a hydrocarbon group having 14 to 24 carbon atoms and one unsaturated bond, and a liposome stabilizer, and the peptide is bound to the surface of the liposome; a cytotoxic T lymphocyte activator containing the peptide-bound liposome; and a hepatitis C virus vaccine.
摘要翻译： 本发明提供肽结合的脂质体，其中肽含有在丙型肝炎病毒NS3蛋白的氨基酸序列中长度不少于9个氨基酸的部分氨基酸序列，长度为9至11个氨基酸， 并且能够诱导细胞毒性T淋巴细胞，脂质体含有含有14〜24个碳原子的酰基和1个不饱和键或14〜24个碳原子的烃基和1个不饱和键的磷脂和脂质体稳定剂， 肽结合到脂质体的表面; 含有肽结合脂质体的细胞毒性T淋巴细胞激活剂; 和丙型肝炎病毒疫苗。
-
公开(公告)号：EP2221368B1
公开(公告)日：2014-03-26
申请号：EP08846317.9
申请日：2008-11-07
申请人： JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES , The Research Foundation for Microbial Diseases of Osaka University
IPC分类号： A61K31/711 , C07K14/005 , A61K39/12
CPC分类号： A61K39/12 , A61K31/711 , A61K2039/5258 , C07K14/005 , C12N2770/24122 , C12N2770/24134 , Y02A50/394
摘要： The present invention provides virus-like particles (VLP) highly secreting or producing signal peptide obtained by altering a signal sequence derived from West Nile virus (WNV), the signal peptide, a WNV VLP secretion expression vector containing a nucleic acid encoding prM protein and E protein, a WNP VLP highly secreting or producing animal cell line harboring the vector, a WNV vaccine containing WNV VLP obtained by the cell line as an active ingredient, and a WNV DNA vaccine containing the ALP secretion expression vector as an active ingredient.
-
公开(公告)号：EP2368899B8
公开(公告)日：2017-10-18
申请号：EP09829169.3
申请日：2009-11-27
申请人： JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES , NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY , Saitama Medical University , NOF CORPORATION
IPC分类号： C07K7/06 , A61K9/127 , A61K39/00 , A61K47/28 , A61P31/16 , A61P37/04 , A61K9/00 , C07K14/005 , A61K39/145 , A61K39/12
CPC分类号： A61K39/145 , A61K9/0019 , A61K9/127 , A61K9/1277 , A61K39/12 , A61K2039/55555 , A61K2039/55561 , C07K14/005 , C12N2740/16222 , C12N2740/16234
-
公开(公告)号：EP2368899B1
公开(公告)日：2017-09-06
申请号：EP09829169.3
申请日：2009-11-27
申请人： JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES , National University Corporation Hokkaido University , Saitama Medical University , NOF CORPORATION
IPC分类号： C07K7/06 , A61K9/127 , A61K39/00 , A61K47/28 , A61P31/16 , A61P37/04 , A61K9/00 , C07K14/005 , A61K39/145 , A61K39/12
CPC分类号： A61K39/145 , A61K9/0019 , A61K9/127 , A61K9/1277 , A61K39/12 , A61K2039/55555 , A61K2039/55561 , C07K14/005 , C12N2740/16222 , C12N2740/16234
-
8.发明授权
公开(公告)号：EP2413961B1
公开(公告)日：2016-08-17
申请号：EP10714104.6
申请日：2010-03-31
申请人： JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES , THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY , Toko Yakuhin Kogyo Kabushiki Kaisha
IPC分类号： A61K39/145 , A61K39/39 , C07K14/11 , A61K39/00 , A61K39/12
CPC分类号： A61K39/145 , A61K39/12 , A61K39/39 , A61K2039/525 , A61K2039/5254 , A61K2039/543 , A61K2039/55555 , A61K2039/55561 , A61K2039/58 , A61K2039/6093 , C12N2760/16134
-
公开(公告)号：EP4317174A1
公开(公告)日：2024-02-07
申请号：EP22775599.8
申请日：2022-03-22
申请人： Peptiaid Inc , Japan as Represented by The Director-General of National Institute of Infectious Diseases
发明人： WATASHI, Koichi , OHASHI, Hirofumi , MASUYA, Keiichi , OHUCHI, Masaki , KURASAKI, Haruaki , MATSUI, Katsuma , NAGASAWA, Takayuki , YAMAMOTO, Junpei , NAGATOMO, Kazutaka , SUDO, Kei , NAKAMURA, Naoko , YOSHIDA, Koji , SHIMADA, Yoshiaki , NIIMI, Tatsuya , MASUDA, Yoshiaki , IWATA, Naoko , SHIWA, Nozomi , NAGATA, Noriyo , SUZUKI, Tadaki , KITAMURA, Hidetomo
IPC分类号： C07K7/08 , A61K38/10 , A61K38/12 , A61K39/395 , A61P31/14 , G01N33/569
摘要： The present invention relates to a peptide and a composition comprising the peptide. This peptide of the present invention comprises the following amino acid sequence: MeA-MeF-S-Cha-Y-S-Y-Y-R-R-Cha-C (SEQ ID NO: 2) or an amino acid sequence having a substitution, addition, deletion, or insertion in 1 to 10 amino acid residues selected from the group consisting of amino acid residues at positions 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 in the above amino acid sequence.
-
公开(公告)号：EP3744847A1
公开(公告)日：2020-12-02
申请号：EP19740775.2
申请日：2019-01-21
申请人： Japan as Represented by The Director-General of National Institute of Infectious Diseases , ID Pharma Co., Ltd.
发明人： MATANO, Tetsuro , ISHII, Hiroshi , INOUE, Makoto , HIRONAKA, Takashi , SHU, Tsugumine , MORI, Toyotaka
IPC分类号： C12N15/49 , A61K38/10 , A61K39/21 , A61P31/18 , A61P37/06 , C07K19/00 , C12N15/86 , C12P21/02 , A61K38/08 , C07K14/155
摘要： The present invention provides polypeptides for selectively inducing target antigen-specific CD8-positive T-cell responses. Since induction of human immunodeficiency virus (HIV)-specific CD4-positive T-cell responses by vaccine could promote HIV infection, an HIV vaccine antigen that selectively induces HIV-specific CD8-positive T-cell responses would be useful if obtained. Thus, in the present invention, polypeptide antigens were designed in which 8- to 12-residue amino acid sequences divided from the amino acid sequence of a target antigen protein were connected in an order different from that of the original amino acid sequence. DNA and viral vector vaccines expressing these antigens were tested by inoculation into monkeys. As a result, they were shown to be able to efficiently induce antigen-specific CD8-positive T-cell responses in a selective manner. The instant antigens may be useful as vaccine antigens that induce CD8-positive T cells in a highly selective manner.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.02 秒)
